AtriCure (ATRC) CMO granted stock awards, uses shares to cover taxes

Rhea-AI Filing Summary

AtriCure, Inc. Chief Marketing & Strategy Officer Justin J. Noznesky reported equity compensation and related tax withholding in company stock. He acquired 27,991 shares through a new restricted stock award and 15,198 shares from a performance share award that vested after meeting company performance and service requirements. To cover tax obligations on vested awards, he transferred 15,586 shares back to the company at a price of $31.26 per share, leaving him with 106,401 shares of common stock held directly.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Noznesky Justin J

Role Chief Mktg & Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,991	$0.00	--
Grant/Award	Common Stock	15,198	$0.00	--
Tax Withholding	Common Stock	15,586	$31.26	$487K

Holdings After Transaction: Common Stock — 106,789 shares (Direct)

Footnotes (1)

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Noznesky Justin J

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Mktg & Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		27,991	A	$0(1)	106,789	D
Common Stock	03/01/2026		A		15,198	A	$0(2)	121,987	D
Common Stock	03/01/2026		F		15,586(3)	D	$31.26	106,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

2. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

3. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Remarks:

	/s/ Justin J. Noznesky	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AtriCure (ATRC) executive Justin Noznesky report?

Justin Noznesky reported equity awards and a tax-related share transfer. He received 27,991 restricted shares and 15,198 performance-based shares, then transferred 15,586 shares back to AtriCure to satisfy tax withholding obligations tied to vested awards.

Were Justin Noznesky’s AtriCure (ATRC) share transactions open-market buys or sells?

No, the reported transactions were equity compensation and tax withholding, not open-market trades. Shares were granted under AtriCure’s 2023 Stock Incentive Plan, and some were transferred back to the company solely to cover associated tax liabilities on vested awards.

How many AtriCure (ATRC) shares did Justin Noznesky acquire through awards?

He acquired 27,991 shares via a restricted stock award and 15,198 shares from a performance share award. Both were granted under AtriCure’s 2023 Stock Incentive Plan, with the performance award vesting after company performance goals and service requirements were satisfied.

What are the vesting terms of Justin Noznesky’s new AtriCure restricted stock award?

The new restricted stock award of 27,991 AtriCure shares vests over three years. One third of the shares vest on each of the one-, two-, and three-year anniversaries of the grant date, subject to continued service under the 2023 Stock Incentive Plan.

Why did Justin Noznesky transfer AtriCure (ATRC) shares back to the company?

He transferred 15,586 shares back to AtriCure to satisfy tax withholding obligations on vested equity awards. This tax-withholding disposition used shares acquired from restricted stock or performance share awards instead of cash, at a reported price of $31.26 per share.

How many AtriCure (ATRC) shares does Justin Noznesky hold after these transactions?

Following the reported equity grants and tax-withholding transfer, Justin Noznesky directly holds 106,401 shares of AtriCure common stock. This figure reflects his position after receiving new awards and surrendering shares to the company to cover related tax liabilities.